Today Pfizer and BioNTech have jointly announced they are prepared to begin their Phase II/III global trials for their COVID-19 vaccine partnership. Following on review of Phase I/II trial results, the partnership worked with the FDA to select BNT162b2 as the vaccine candidate in the next phases.
Pfizer and BioNTech biopharmaceutics announced today a $1.95 billion dollar agreement with the U.S. government for 100 million doses of the partnership's BNT162 program vaccine.
In a news release today, the BNT162b1 COVID-19 vaccine under development by Pfizer and BioNTech displayed early positive results in producing neutralizing antibodies from the partnership's Phase I/II trial.
As manufacturers worldwide race to develop the first viable COVID-19 vaccine faster than any vaccine ever developed in human history, late November remains an important date in the United States to vaccinate a large number of Americans.
The first vaccines for the COVID-19 pandemic may arrive in just shy of two months from today according to the World Health Organization (WHO) and several vaccine manufacturers.
We spoke with Pfizer today and confirmed October remains feasible but is contingent on successful aquisition of an Emergency Use Declaration
The South China Morning Post reported today some vaccines may become available as early as this autumn. Pfizer, meanwhile hinted their vaccine could come as early as October of this year.
In a report from the Associated French Press, Pfizer head Albert Bourla claimed a vaccine may come as early as the end of October, acknowledging the date requires an ideal path.